<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343183</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001051</org_study_id>
    <nct_id>NCT04343183</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection</brief_title>
  <official_title>Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who meet inclusion criteria will be randomized into treatment vs control group.
      Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, patients will be randomized into treatment vs control group. Both
      populations will receive the same inpatient medical treatment. All patients in the treatment
      group will undergo hyperbaric oxygen therapy under the same treatment protocol. After
      completion of the treatment protocol, specific study endpoints will be compared between the
      treatment and control groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will utilize a single-center sequential two-parallel-group (HBOT/Standard care) randomized controlled design with 2 looks to allow for early stop due to clear benefit/harm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The biostatistician and radiologist will not know which group received HBOT.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease incidence of intubation by 30% or greater</measure>
    <time_frame>one month</time_frame>
    <description>Compare rates of intubation between treatment and control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease renal injury</measure>
    <time_frame>one month</time_frame>
    <description>Measure Glomerular Filtration Rate (GFR) and compare between treatment and control groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>HBOT treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hyperbaric oxygen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperbaric Oxygen Therapy</intervention_name>
    <description>Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.</description>
    <arm_group_label>HBOT treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult inpatients &gt;18 years old

          -  Positive PCR COVID-19 testing

          -  CT evidence of interstitial opacity

          -  Oxygen saturation &lt;90% on room air

          -  pO2 = 55-70.

        Exclusion Criteria:

          -  Increased oxygen requirements

          -  Hemodynamic instability (MAP&lt;65)

          -  Bradycardia (HR&lt;50)

          -  History of seizure disorder

          -  Pneumothorax

          -  GFR&lt;30

          -  Hemodialysis

          -  Refractory anxiety/claustrophobia

          -  Current pregnancy

          -  Uncorrectable hypoglycemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery S Kuo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ochsner Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John F Engle, MD</last_name>
    <phone>985-768-8918</phone>
    <email>englemd94@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Lindley, MD</last_name>
    <phone>504-957-3326</phone>
    <email>mdlindley@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>John Engle</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participants will be given a unique unidentifiable study ID number and all data will be recorded accorded to unidentifiable number to protect the patients personal health information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

